HIMS

TentativeAI MemoPost-earnings T+3

Hims Hers Health

As of 2026-08-13/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-13 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

report lacks a dated company-specific catalyst beyond generic cadence for its sector profile; peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

medium

Horizon

—

Key catalyst

Raised FY2026 outlook and Q3 guide • 2026-11-11

Base target: $33 / p=50% prob

Biggest risk

Growth is coming with substantially weaker gross margin, a larger net loss, lower adjusted EBITDA, and negative operating cash flow. The key question is whether international, weight-loss, and technology investment can scale without prolonged margin compression. Secondary headlines similarly frame strong growth against profitability concerns, but do not provide a verified analyst consensus or revision set.

Invalidation

Break below $23 or thesis failure.

What would change my mind?

The Q2 print shows strong top-line reacceleration, subscriber growth, higher revenue per subscriber, and a materially higher FY2026 revenue outlook. International expansion and AI/technology investment could support the longer-term platform thesis. [#SEC-8K-2026-08-10]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-13

Base target

$33

p=50%

Bull target

$38

p=25%

Bear target

$23

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings margin and cash-flow digestion
Subscriber and international growth
The Q2 print shows strong top-line reacceleration, subscriber growth, higher revenue per subscriber, and a materially higher FY2026 revenue outlook.

BearKey bullets

Execution risk from rapid international expansion and the Eucalyptus integration.
Gross margin compression from 76% to 64% year over year.
Negative operating cash flow and negative free cash flow in Q2.

WatchKey bullets

Raised FY2026 outlook and Q3 guide

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $33 (p=50%)

Target spread vs base: +17% / -31%

Scenario probabilities

Bull Target: $38 (p=25%)Base Target: $33 (p=50%)Bear Target: $23 (p=25%)

Commentary

The post-earnings tone is mixed: strong revenue, subscriber growth, and raised guidance are offset by weaker margins, losses, and cash burn. The supplied RankAlpha anchor was $29.97 on 2026-08-12, but an attributable post-release move versus the pre-earnings close is not provided. Reliable post-print analyst revisions and target changes are unavailable, and the peer set has only one reasonably direct operating comparator. Social and options inputs were not available in the evidence packet, so confidence remains reduced.

As of 2026-08-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings margin and cash-flow digestion
Subscriber and international growth

Scenarios

Bull Target (Scenario probability)

$38 / p=25% prob

Base Target (Scenario probability)

$33 / p=50% prob

Bear Target (Scenario probability)

$23 / p=25% prob

Analysis 2026-08-13 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.12

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-11
Raised FY2026 outlook and Q3 guide
Q2 revenue reached $753.2 million, up 38% year over year, while management raised FY2026 revenue guidance to $3.1-$3.3 billion and provided Q3 revenue guidance of $880-$900 million. [#SEC-8K-2026-08-10]
Prob 75.00% • Move 8.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Post-earnings margin and cash-flow digestion
2026-11-11
Gross margin fell to 64% from 76%, net loss was $86.3 million, adjusted EBITDA declined to $60.3 million, and operating cash flow remained negative. Secondary headlines emphasize the tension between strong revenue growth and profitability pressure; analyst revision data is unavailable. [#SEC-8K-2026-08-10]
Prob 70% • Move -7% • Priced-in 50%

Long-term Catalysts

Months to a year

Subscriber and international growth
2027-08-13
Subscribers rose 19% year over year to nearly 2.9 million, with international revenue exceeding 17-fold year over year after the Eucalyptus acquisition. [#SEC-8K-2026-08-10]
Prob 65% • Move 15% • Priced-in 55%

Risks

Execution risk from rapid international expansion and the Eucalyptus integration.
Gross margin compression from 76% to 64% year over year.
Negative operating cash flow and negative free cash flow in Q2.
Net loss and adjusted EBITDA deterioration despite strong revenue growth.
Post-earnings analyst target changes, estimate revisions, and attributable market-reaction data are unavailable.
Recent Form 4 data shows open-market sales by the CFO and CMO; this is a sentiment signal only, not evidence of operating performance. [#SEC-FORM4-2026-07-20]

Peers

Symbol	Summary
HNGE	The closest available digital-health operating comparison in the packet, although business mix and scale differ materially. It is useful for platform-growth context, not as a tight valuation match.
ABT	Broad healthcare and medical-device comparator only; not a direct operating peer for HIMS.
BSX	Broad healthcare and medical-device comparator only; not a direct operating peer for HIMS. The packet does not support a second close digital-health peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-13

Loading AI feed…

Symbol

Summary

HNGE

The closest available digital-health operating comparison in the packet, although business mix and scale differ materially. It is useful for platform-growth context, not as a tight valuation match.

ABT

Broad healthcare and medical-device comparator only; not a direct operating peer for HIMS.

BSX

Broad healthcare and medical-device comparator only; not a direct operating peer for HIMS. The packet does not support a second close digital-health peer.